Five shareholder derivative lawsuits have piled up against biopharmaceutical company BioXcel Therapeutics Inc. over the past seven months after a putative securities class action that alleged a principal investigator failed to follow proper study guidelines and possibly fabricated emails in a Food and Drug Administration inspection.

BioXcel markets itself as a biopharmaceutical company that uses artificial intelligence to develop neurological medicines.